Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a year. I think now is a terrific opportunity to scoop up shares of Novo on the ...

Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be ...

The report highlighted that Novo Nordisk currently charges Americans $969 a month for diabetes therapy Ozempic, but just $155 in Canada and $59 in Germany. Similarly, the list price for obesity ...

Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00 ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

BMO Capital lowered the firm’s price target on Novo Nordisk (NVO) to $105 from $156 but keeps an Outperform rating on the shares. The ...

The U.S. FDA has approved Alhemo, given as once-daily injections, to help prevent bleeds in patients with hemophilia A or B ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

"And then mid-year for Lilly, we have Orforglipron, which is their small molecule pill GLP-1, which could really open up the market. So I feel like Novo is kind of losing its pep a little bit," he ...

At the moment, the hottest GLP-1 treatment is Ozempic. Danish pharmaceutical leader Novo Nordisk (NYSE: NVO) is the brains behind Ozempic, as well as sibling GLP-1 medications including Wegovy ...

Novo Nordisk's shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema ...